Search results for "REPLACEMENT THERAPY"

showing 10 items of 289 documents

Nutrition in Pediatric Kidney Disease

2018

AbstractNutrition has a major impact on the health of children with chronic kidney disease (CKD). Special diets and additional replacement therapies may be chosen according to the specific renal disease. Persistent low-grade inflammation, which contributes to CKD-associated cardiovascular and all-cause mortality, protein-energy wasting, oxidative stress, acidosis, chronic and recurrent infections, and altered metabolism of adipose tissue may result from dietary deficits and are important targets for nutritive intervention. Therefore, many guidelines have been developed regarding nutrient intake adequation to assist pediatricians treating these children. Acute kidney injury (AKI) has multifa…

medicine.medical_specialtybusiness.industrymedicine.medical_treatment030232 urology & nephrologyAcute kidney injuryDiseaseurologic and male genital diseasesMicronutrientmedicine.disease03 medical and health sciencesMalnutrition0302 clinical medicine030225 pediatricsPediatrics Perinatology and Child HealthmedicineEtiologySurgeryRenal replacement therapymedicine.symptombusinessIntensive care medicineWastingKidney diseaseJournal of Child Science
researchProduct

Delayed versus early initiation of renal replacement therapy for severe acute kidney injury: a systematic review and individual patient data meta-ana…

2020

Summary Background The timing of renal replacement therapy (RRT) for severe acute kidney injury is highly debated when no life-threatening complications are present. We assessed whether a strategy of delayed versus early RRT initiation affects 28-day survival in critically ill adults with severe acute kidney injury. Methods In this systematic review and individual patient data meta-analysis, we searched MEDLINE (via PubMed), Embase, and the Cochrane Central Register of Controlled Trials for randomised trials published from April 1, 2008, to Dec 20, 2019, that compared delayed and early RRT initiation strategies in patients with severe acute kidney injury. Trials were eligible for inclusion …

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentAbsolute risk reductionAcute kidney injuryGeneral Medicine030204 cardiovascular system & hematologyurologic and male genital diseasesmedicine.diseaseClinical trial03 medical and health sciences0302 clinical medicineInternal medicineRelative riskMeta-analysisSeverity of illnessmedicine030212 general & internal medicineRenal replacement therapybusinessKidney diseaseThe Lancet
researchProduct

Optimizing ceftolozane-tazobactam dosage during continuous renal replacement therapy: some nuances

2020

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentCEFTOLOZANE/TAZOBACTAMMEDLINElcsh:Medical emergencies. Critical care. Intensive care. First aidlcsh:RC86-88.9Critical Care and Intensive Care MedicineTazobactammedicineRenal replacement therapyIntensive care medicinebusinessmedicine.drugCritical Care
researchProduct

Smoking Cessation in Individuals with Depression

1999

Current, historical and subclinical depression have been linked to a high incidence of cigarette smoking and smoking cessation relapse. This review discusses the efficacy, suitability and other treatment issues involved in using nicotine replacement therapy, antidepressant treatment and cognitive-behavioural interventions to help depressed smokers quit smoking. It is recommended that prior to choosing a smoking cessation treatment regimen, assessment should be made of: (i) current and past history of depression; (ii) nicotine dependency; and (iii) other risk factors (e.g. family history of depression, past difficulty in quitting) for relapse. For those individuals who are highly nicotine de…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentNicotine replacement therapymedicine.diseaseNicotinePsychiatry and Mental healthPharmacotherapymedicineAntidepressantSmoking cessationMajor depressive disorderPharmacology (medical)Neurology (clinical)Family historyPsychiatrybusinessDepression (differential diagnoses)medicine.drugCNS Drugs
researchProduct

Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing

2020

Abstract Background Few data are reported in the literature about the outcome of patients with severe extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) infections treated with ceftolozane/tazobactam (C/T), in empiric or definitive therapy. Methods A multicenter retrospective study was performed in Italy (June 2016–June 2019). Successful clinical outcome was defined as complete resolution of clinical signs/symptoms related to ESBL-E infection and lack of microbiological evidence of infection. The primary end point was to identify predictors of clinical failure of C/T therapy. Results C/T treatment was documented in 153 patients: pneumonia was the most common diagnosis (n = 46…

medicine.medical_specialtyceftolozane/tazobactammedicine.medical_treatmentCRRTTazobactamEnterobacteralesEnterobacteraleInternal medicineCRRT; ESBL; Enterobacterales; ceftolozane/tazobactam; septic shockMajor ArticlemedicineClinical endpointRenal replacement therapybusiness.industrySeptic shockRetrospective cohort studyOdds ratiomedicine.diseaseCeftolozane/tazobactam; CRRT; Enterobacterales; ESBL; Septic shockAcademicSubjects/MED00290Infectious DiseasesOncologyESBLseptic shockCeftolozanebusinessEmpiric therapymedicine.drugOpen forum infectious diseases
researchProduct

Pathophysiologische Aspekte hirnstruktureller Veränderungen bei Morbus Fabry: Literaturübersicht

2006

Fabry Disease (FD) is a rare X-linked lysosomal storage disorder caused by deficiency of alpha-galactosidase A (alpha-GAL) enzyme activity. Neutral glycosphingolipides (esp. Gb3) accumulate in lysosomes of several tissues, particularly in vascular endothelium and smooth muscle cells. Cerebral manifestations that might be mainly due to progressive cerebrovascular dysfunction, are one major and often life-threatening burden of the disease. We reviewed the present literature concerning brain structural alterations in FD and discuss the possibly relevant underlying pathophysiological aspects of these disturbances. Cerebrovascular events (TIA, stroke) occur in FD at a rather early age. In female…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryPhysiologyMagnetic resonance imagingDiseaseEnzyme replacement therapymedicine.diseaseFabry diseaseHyperintensityAngiopathyPsychiatry and Mental healthNeurologyInternal medicinemedicineCardiologyNeurology (clinical)businessStrokePathologicalFortschritte der Neurologie · Psychiatrie
researchProduct

INT-009 Pharmacokinetics of linezolid and meropenem in intensive care unit patients receiving continuous renal replacement therapy

2016

Background Intensive care unit (ICU) patients often suffer from infections and acute renal failure and might need continuous renal replacement therapy commonly applied by veno-venous hemodialysis (CVVHD) or hemodiafiltration (CVVHDF). In this case there are no dosage recommendations in the product informations of antibiotics and literature data are scarce. The risk for therapy failure, development of resistance and adverse drug effects is elevated. Purpose Aim of the presented study was to find out if standard therapy of Linezolid (LZ) and Meropenem (MP) results in adequate plasma levels in surgical ICU patients receiving CVVHD(F). Materials and Methods Surgical ICU patients receiving CVVHD…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industrymedicine.drug_classmedicine.medical_treatmentAntibioticsMeropenemIntensive care unitSurgerylaw.inventionchemistry.chemical_compoundchemistryPharmacokineticslawTherapeutic drug monitoringAnesthesiaLinezolidmedicineRenal replacement therapyHemodialysisGeneral Pharmacology Toxicology and Pharmaceuticsbusinessmedicine.drugEuropean Journal of Hospital Pharmacy
researchProduct

Two-year prospective, randomized trial comparing an innovative twice-a-week progestin regimen with a continuous combined regimen as postmenopausal ho…

1999

Abstract Objective: To compare compliance, symptom control, bleeding patterns, endometrial response, and lipid changes in postmenopausal women treated with transdermal E 2 and a regimen of either intermittent or continuous dosing of progestin. Design: Randomized, prospective study. Setting: Menopausal Outpatient Clinic at an academic tertiary care hospital. Patient(s): One hundred women who had reached menopause naturally and had been amenorrheic for at least 1 year. Fifty women were randomly assigned to receive each regimen. Intervention(s): All patients received 50-μg E 2 patches and medroxyprogesterone acetate, either 5 mg twice per week or 2.5 mg daily. The bleeding pattern was register…

medicine.medical_specialtymedicine.drug_classMedroxyprogesteroneMedroxyprogesterone AcetateAdministration CutaneousEndometriumInternal medicinemedicineMedroxyprogesterone acetateOutpatient clinicHumansProspective StudiesProspective cohort studyAgedmedicine.diagnostic_testEstradiolProgesterone Congenersbusiness.industryEstrogen Replacement TherapyObstetrics and GynecologyMiddle Agedmedicine.diseaseLipidsSurgeryMenstruationMenopauseRegimenReproductive MedicinePatient ComplianceFemaleProgestinsbusinessProgestinmedicine.drugEndometrial biopsyFertility and sterility
researchProduct

Chronic kidney disease and dyslipidaemia

2016

Chronic kidney disease (CKD) has to be considered as a high, or even very high risk cardiovascular risk condition, since it leads to an increase in cardiovascular mortality that continues to increase as the disease progresses. An early diagnosis of CKD is required, together with an adequate identification of the risk factors, in order to slow down its progression to more severe states, prevent complications, and to delay, whenever possible, the need for renal replacement therapy. Dyslipidaemia is a factor of the progression of CKD that increases the risk in developing atherosclerosis and its complications. Its proper control contributes to reducing the elevated cardiovascular morbidity and …

medicine.medical_specialtymedicine.medical_treatmentRenal functionDisease030204 cardiovascular system & hematologyurologic and male genital diseases03 medical and health sciences0302 clinical medicineRisk FactorsmedicineHumans030212 general & internal medicineRenal replacement therapyRenal Insufficiency ChronicIntensive care medicineDyslipidemiasGeneral Environmental ScienceCardiovascular mortalitybusiness.industryAnticholesteremic AgentsGeneral EngineeringCholesterol LDLmedicine.diseaseRenal Replacement TherapyCardiovascular DiseasesRenal transplantDisease ProgressionPhysical therapyGeneral Earth and Planetary SciencesHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessVery high riskDyslipidemiaKidney diseaseClínica e Investigación en Arteriosclerosis (English Edition)
researchProduct

Official Statement of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) on Electronic Cigarettes and IQOS®.

2019

The use of novel tobacco products, particularly the electronic cigarette (EC) and partial tobacco combustion devices (HnB systems: Heat not Burn), has increased exponentially, particularly among adolescents and young people. The health authorities and scientific societies have shown concern about issues surrounding safety and effectiveness (as a method of smoking cessation). A study of the available scientific evidence has concluded that the safety of the vapor or fumes inhaled by the users of these devices cannot be guaranteed. Contradictory results from various clinical trials and meta-analyses also mean that these devices cannot be recommended for their effectiveness in cessation, especi…

medicine.medical_specialtymedicine.medical_treatmentRespiratory SystemElectronic Nicotine Delivery Systemslaw.inventionScientific evidence03 medical and health scienceschemistry.chemical_compound0302 clinical medicinelawInternal medicineNeoplasmsmedicinePulmonary MedicineHumansVareniclineSocieties MedicalBupropionAerosolsbusiness.industryThoracic SurgeryGeneral MedicineNicotine replacement therapyTobacco Use Cessation DevicesClinical trialPulmonology030228 respiratory systemchemistryCardiovascular DiseasesSpainFamily medicineSmoking cessationSmoking CessationbusinessElectronic cigarettemedicine.drugArchivos de bronconeumologia
researchProduct